Overview
Analysis
SHPG4260178 analysis
Key facts
Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL.
Go deeper with bond data
Access the most important data for bonds including coupon rates, issue ratings, redemption data and more.